Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Secondary Investor Saints Capital Offers VCs A Third Way Out

This article was originally published in Start Up

Executive Summary

Secondary firms such as Saints, which is raising a $300 million seventh fund, step in to acquire stakes from other VCs at the end of their funds’ lifespans. With a biotech VC shakeout in progress, the secondaries are banking on more opportunities soon.

You may also be interested in...

Secondary Directs: Tonic for the Biotech Venture Financing Model?

With the biotech VC model battered by miserable public markets on the one hand and too-few M&A exits on the other, some firms with adequate resources are looking to lower their total investment cost by buying, at big discounts, portfolio assets from other investors. But secondary investing is a very different game. Because the model and returns are so different, most VCs still say they're likely to avoid secondary direct investing - but given the longer-term problems of the VC model, some may begin to adopt it as a short-term tactic.

OTC Codeine Is 'Safe And Effective' – UK Industry Responds To BBC Exposé

Will the UK follow other countries and reverse-switch codeine to prescription-only status? British industry association, the PAGB, responds to a BBC documentary questioning the safety and efficacy of OTC codeine.

French OTC Industry Frustrated By Regulatory Clampdown in 2019

Speaking exclusively to HBW Insight, French OTC association Afipa reflects on a difficult 2019 which saw tighter restrictions introduced on the sale of popular consumer health products. The trade group believes the industry's best prospects for a brighter future are rebuilding relations with national drug regulator ANSM and to getting self-care higher up the agenda of the French government.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts